Introduction {#s1}
============

Ribonucleotides play a central role in cellular physiology, and complex regulatory networks maintain optimal nucleotide levels according to the variable metabolic state of the cell ([@bib44]). Under most conditions, cells rely on salvage pathways to regenerate degradation products and maintain nucleotide pools. However when nucleotide demand is high, for example during cellular proliferation, flux through de novo nucleotide biosynthesis pathways is up-regulated.

The enzyme IMP dehydrogenase (IMPDH) catalyzes the first committed step in guanine nucleotide synthesis. Initiation of purine nucleotide biosynthesis is tightly regulated by downstream adenine and guanine nucleotide products. Balancing the flux through these parallel synthesis pathways, which share the precursor inosine monophosphate (IMP), is essential for cellular homeostasis ([Figure 1A](#fig1){ref-type="fig"}) ([@bib4]). IMPDH is regulated transcriptionally, post-translationally, and allosterically ([@bib30]). In vertebrates, two IMPDH isoforms, (83% identical in humans), have differential expression patterns ([@bib21]; [@bib52]). IMPDH1 is constitutively expressed at low levels in most tissues, while IMPDH2 is generally upregulated in proliferating tissues ([@bib18]; [@bib28]; [@bib35]; [@bib65]). In mice, knockout of IMPDH1 results in only very minor vision defects, whereas knockout of IMPDH2 is embryonic lethal ([@bib3]; [@bib27]; [@bib26]).

![IMPDH structure and function.\
(**A**) De novo purine nucleotide biosynthesis pathways. (**B**) IMPDH consists of a catalytic domain with two substrate binding sites (green), and a regulatory Bateman domain (pink) with three allosteric binding sites on the Bateman domain numbered 1,2,3. (**C**) Bound nucleotides promote regulatory domain dimerization, forming reversible IMPDH octamers that may be active or inhibited. Opposing tetramers colored light green and light pink. (**D**) Human IMPDH2 assembles into filaments composed of canonical octamers.](elife-53243-fig1){#fig1}

IMPDH reversibly assembles into filaments in vertebrate cells and tissues, which is thought to provide an additional layer of regulation ([@bib17]; [@bib37]; [@bib73]). Self-assembly into filamentous polymers has recently been observed in cells for a large number of metabolic enzymes ([@bib51]; [@bib54]; [@bib53]; [@bib56]; [@bib66]; [@bib79]). Filament assembly is typically induced by changes in metabolic conditions, and the enzymes involved are key regulatory or branch point enzymes, supporting the hypothesis that self-assembly is a general mechanism of regulating flux through specific metabolic pathways ([@bib6]). In the few cases where the structure and function of metabolic filaments have been described, they show that the polymers directly influence enzyme activity by stabilizing specific active or inhibited conformations ([@bib32]; [@bib42]; [@bib46]; [@bib47]; [@bib70]; [@bib78]). Low resolution structural studies have shown that IMPDH2 filaments are flexible, adopting both active and inhibited conformations, and that filament assembly does not directly affect enzyme activity ([@bib5]; [@bib43]).

Guanine deprivation induces assembly of IMPDH into micron-scale ultrastructures composed of bundled filaments, which disassemble once homeostasis is restored ([@bib15]; [@bib38]; [@bib43]; [@bib73]). Additional stimuli that alter IMPDH catalytic flux result in assembly, including increased intracellular IMP, and treatment with IMPDH inhibitors or other anti-proliferative drugs ([@bib19]; [@bib37]; [@bib39]; [@bib40]). In vivo, IMPDH assembly is seen mainly in cases of high nucleotide demand, for example assembly is correlated with proliferation of mouse induced pluripotent stem cells and human T-cell activation ([@bib16]; [@bib22]; [@bib40]). However, the molecular mechanisms that underlie assembly-dependent regulation of IMPDH have not been described.

The catalytic mechanism and the structures of IMPDH monomers and defined oligomers are well-described [@bib30]. IMPDH forms stable tetramers, each protomer consisting of a catalytic domain and a regulatory Bateman domain ([Figure 1B](#fig1){ref-type="fig"}). The enzyme converts IMP to xanthosine monophosphate (XMP) and requires NAD^+^ as a cofactor for a complex multi-stage catalysis requiring rearrangements of active site loops that close around the substrate upon binding, and then must reopen to allow release of product. The regulatory domain contains three allosteric sites that bind adenine and guanine nucleotides ([@bib13]). Sites 1 and 2 are canonical cystathionine beta synthase motifs that bind either ATP/ADP or GTP/GDP, and are conserved among IMPDH homologues ([@bib9]; [@bib24]; [@bib33]; [@bib64]). Site 3 is a non-canonical site located at the interface between domains that binds only GTP/GDP ([@bib13]).

In eukaryotes, adenine and guanine nucleotides allosterically modulate IMPDH activity by altering oligomeric state ([@bib14]; [@bib25]). IMPDH tetramers reversibly assemble into octamers when nucleotides bind the two canonical sites and drive dimerization of Bateman domains ([Figure 1C](#fig1){ref-type="fig"}). Bound adenines promote an extended conformation in which the active sites are free to open and close as needed for catalysis. GTP/GDP binding induces a compressed conformation by changing the relative orientation of the two domains. This brings the active sites of opposing tetramers tightly together, forming an interdigitated pseudo beta-barrel that prevents reopening and product release and inhibits IMPDH activity by a mechanism described as a 'conformational switch' between extended and compressed states ([@bib14]; [@bib13]; [@bib25]). Because inhibition requires interactions between two opposing tetramers, this switch is functionally relevant in only the octameric state.

In vitro treatment with ATP or GTP induces assembly of human IMPDH into filaments composed of stacked octamers interacting through their catalytic domains ([Figure 1D](#fig1){ref-type="fig"}) ([@bib5]; [@bib25]; [@bib43]). Filament segments can both extend and compress, and assembly does not have a direct effect on the activity of IMPDH2 ([@bib5]). Importantly, mutations that block assembly of IMPDH filaments in vitro also prevent assembly of the large IMPDH bundles observed in cells, supporting the functional relevance of in vitro reconstituted filaments.

In this study, we present a series of cryo-electron microscopy (cryo-EM) structures of human IMPDH2. Structures of the enzyme treated with multiple combinations of substrates (IMP, NAD+) and allosteric effectors (ATP, GTP), in both filament and non-filament assembly states, demonstrate the extreme conformational plasticity of the enzyme. These structures define the interactions that drive filament assembly, and we show that in vitro IMPDH2 filament assembly is sensitive to the same conditions that promote assembly in cells: high IMP levels and low guanine nucleotide levels ([@bib40]). Finally, we show that filament assembly tunes sensitivity to GTP inhibition by stabilizing a conformation that reduces affinity for GTP. In other enzyme polymers with known functions, assembly directly up or down regulates activity; the resistance to feedback inhibition observed in IMPDH2 filaments demonstrates a new role for enzyme self-assembly and reflects the diversity of allosteric regulatory mechanisms in metabolic filaments.

From these data, we have developed a model (described in more detail below), in which IMPDH2 filament assembly modulates known conformational changes of the enzyme to alter catalytic flux in response to proliferative signaling. Eukaryotic IMPDH activity is regulated in response to adenine or guanine nucleotides by extension or compression, respectively, of the Bateman domains. Under physiologically high substrate (IMP) levels, assembled filaments resist the compressed, inhibited, state, independent of guanine levels. This allows for a third regulatory state in which the enzyme is able to resist feedback inhibition in response to proliferative signaling.

Results {#s2}
=======

IMPDH2 filaments are conformationally heterogeneous {#s2-1}
---------------------------------------------------

We first characterized IMPDH2 filaments assembled in vitro by addition of ATP ([@bib5]). The affinity of IMPDH2 for ATP has not been directly measured but we found ATP concentrations as low as 1 μM sufficient to induce assembly ([Figure 2A](#fig2){ref-type="fig"}). We prepared cryo-EM grids of ATP-assembled filaments and found that in the absence of other ligands, IMPDH2 filaments are extremely flexible ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Two-dimensional class averages confirmed our prior observation from negative stain that the filaments are composed of conformationally heterogeneous octamers stacked head-to-head, resulting in flexible filaments with variable rise and radius of curvature ([Figure 2B](#fig2){ref-type="fig"}). Because these deviations from ideal helical symmetry severely limited attempts at image processing by traditional iterative helical real-space reconstruction, we attempted to produce more structurally homogeneous filaments by addition of IMP or NAD^+^, which stabilize the flexible active site loops ([@bib68]). As previously reported, substrates did not have a direct effect on IMPDH2 filament assembly, and filament assembly did not directly affect enzymatic activity ([Figure 2C--D](#fig2){ref-type="fig"}) ([@bib5]). While the turnover rate we observe here (\~0.05 per second) is somewhat low, these reactions were performed near room temperature (24**°**C); we found that increasing reaction temperature to 37**°**C resulted in increasing Kcat to \~0.1 per second, roughly half what was observed in another recently published study of human IMPDH2 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) ([@bib25]). Unfortunately, addition of IMP and NAD^+^, either alone or in combination, did not significantly reduce filament flexibility ([Figure 2---figure supplement 1B--D](#fig2s1){ref-type="fig"}). Two-dimensional class averages of helical segments again exhibited varying degrees of curvature and showed no correlation of structural states between neighboring IMPDH2 octamers, preventing successful three-dimensional processing with conventional helical approaches ([Figure 2E--G](#fig2){ref-type="fig"}).

![Electron microscopy of uninhibited IMPDH2 filaments.\
(**A**) Negative stain EM of purified human IMPDH2. Treatment with 1 μM ATP induces filament assembly. Scale bar 100 nm. (**B**) Representative 2D class averages from the 2.5 mM ATP cryo-EM dataset. (**C**) Negative stain EM of actively catalyzing IMPDH2 (2 mM IMP, 2 mM NAD^+^), with and without 2 mM ATP. (**D**) Initial velocity of enzyme (2 mM IMP, 2 mM NAD^+^), with and without 2 mM ATP. Average of three replicates, error bars + /- 1 s.D. (**E--G**) Representative 2D class averages from the three uninhibited enzyme cryo-EM datasets, with nucleotide concentrations as indicated at bottom.](elife-53243-fig2){#fig2}

From these 2D class averages we observed that filament flexibility was due to variations in the conformation of filament segments, but that the interface between segments did not vary, and as a consequence this region was better resolved ([Figure 3A](#fig3){ref-type="fig"}). Focused refinement of the filament assembly interface region alone provided a valuable foothold in resolving high resolution structures of all regions of the filaments. We developed a workflow for a single-particle style approach to reconstruction of inherently heterogeneous helical protomers, combining density subtraction, symmetry expansion, focused classification and focused refinement to isolate, classify, and reconstruct discrete sections of filaments for structural characterization ([Figure 2---figure supplement 1E--G](#fig2s1){ref-type="fig"}). This approach provided multiple structures for two different focused regions of IMPDH2 filaments: full octameric segments, and the paired catalytic domain tetramers that constitute the filament assembly interface ([Figure 3B](#fig3){ref-type="fig"}).

![The structures of uninhibited IMPDH2 filaments.\
(**A**) Cryo-EM of IMPDH2 filaments with both substrates (representative 2D class average). (**B**) We resolved two types of structures from IMPDH filaments: the consensus filament assembly interface, and various conformations of filament segments. (**C**) Cryo-EM density for the ATP/IMP/NAD+ consensus filament assembly interface, consisting of two tetramers bound back-to-back (dark and light green) (0.5 mM ATP, 2 mM IMP, 2 mM NAD^+^). (**D**) The filament assembly interface is mediated by the vertebrate-specific N-terminus, in particular a key bridge between Y12 and R356. (**E**) Cryo-EM density for the ATP/IMP/NAD+ fully extended filament segment. Opposing catalytic tetramers (dark and light green), are held separate by their symmetrically extended Bateman domains (dark and light pink). ATP (bright green) is resolvable in the Bateman domains. (**F**) In the fully extended Bateman domains, sites 1 and 2 are occupied by ATP, and site 3 is unformed. (**G**) Cryo-EM density for the best resolved ATP/IMP/NAD+ bent filament segment, in which the two catalytic tetramers are not parallel. (**H**) Filament segment bending results from asymmetric compression of Bateman domains. In this reconstruction, one protomer from each of the two tetramers is compressed, and allosteric site 3 is formed, but unoccupied (black asterisk). (**I**) Summary of the ATP/NAD^+^ cryo-EM dataset (2 mM ATP, 2 mM NAD^+^). The filament assembly interface is unchanged, and filament segments varied from fully extended, to bent, to fully compressed. In the absence of IMP, the flexible active site loops are disordered. (**J**) Summary of the ATP/IMP cryo-EM dataset (2 mM ATP, 3 mM IMP).\
Figure 3---source data 1.Statistics of cryo-EM data collection, reconstruction and model refinement for the ATP/IMP/NAD^+^ dataset.\
Figure 3---source data 2.Statistics of cryo-EM data collection, reconstruction and model refinement for the ATP/NAD^+^ dataset.\
Figure 3---source data 3.Statistics of cryo-EM data collection, reconstruction and model refinement for the ATP/IMP dataset.](elife-53243-fig3){#fig3}

The IMPDH2 filament assembly interface is well-ordered {#s2-2}
------------------------------------------------------

To define the interactions that drive assembly of catalytically active IMPDH2 filaments, we obtained cryo-EM structures of IMPDH2 in three liganded states: 1) ATP/IMP/NAD^+^, 2) ATP/NAD^+^, and 3) ATP/IMP. The three datasets were qualitatively similar. However, because the structures refined to higher resolution when both substrates were present, we focus our analysis here on the ATP/IMP/NAD^+^ dataset. The complete image processing workflow applied to this dataset ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) was also applied to the two single-substrate datasets. From the ATP/IMP/NAD^+^ data we resolved many different structural classes, three best-resolved of which were: the filament assembly interface, and two different reconstructions of octameric filament segments ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). We resolved many conformations of filament segments, however for all segments the filament assembly interface was identical. Therefore the filament assembly interface structure is a dataset consensus structure, an average of every segment included in the dataset. We did not observe any conformational cooperativity in the compressed/extended conformational equilibrium between IMPDH2 octamers sharing a filament assembly interface.

We determined the structure of the ATP/IMP/NAD^+^ consensus filament assembly interface at 3.0 Å resolution ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}, [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). This D4 symmetric region is composed of two symmetrically opposed catalytic domain tetramers. The interface between tetramers is formed by the 12 amino-terminal residues of eight protomers, which each extend from the core of the molecule to bind one catalytic domain on the opposite tetramer, in a shallow surface groove formed by a short helix (476-485), two beta strands (51-63), and two short loops (355-360, 379-380) ([Figure 3D](#fig3){ref-type="fig"}). A key tyrosine/arginine interaction (Y12/R356') anchors the attachment; mutation of either of these residues to alanine was previously shown to abolish assembly, both in vivo and in vitro ([@bib5]). Residues 1--7 make mostly hydrophobic interactions with the catalytic domain, and an embedded arginine (R480') is positioned to hydrogen bond to the I6 backbone carbonyl. These interactions are reciprocal - a protomer extends its N-terminus to a partner and receives the N-terminus of the same partner, creating four pairs of symmetrical interactions at the interface. The overall surface area buried by a single interaction is 2,300 Å^2^, with a total buried area of 9,200 Å^2^ for the multimeric interface.

The N-terminal tail of IMPDH, corresponding to residues 1--28 in IMPDH2, is the least conserved part of the protein, with large variation in length and sequence between phyla, as well as conformational variation among known structures ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}) ([@bib12]; [@bib25]; [@bib41]; [@bib43]; [@bib48]; [@bib57]; [@bib60]; [@bib74]). The residues involved in filament contacts, however, are conserved among chordates, consistent with the fact that IMPDH polymerization has only been reported in vertebrates ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). In previous crystal structures of human and fungal IMPDH, residues 1--11 are unresolved and residues 12--28 are well resolved. In these structures, Asp16 anchors the tail in place through ionic interactions with Arg341/Lys349 of a neighboring protomer, while Val13 and Pro14 make hydrophobic contacts. In the filament structure, however, the Val13/Pro14 contacts are broken and the entire tail is rotated about 30° to position Tyr12 to contact Arg356 across the filament interface ([Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}).

In this consensus structure, the remainder of the catalytic domain is nearly identical to a structure of human hIMPDH2 bound to competitive inhibitors in a previously determined crystal structure (PDB 1nf7, backbone RMSD 0.641 Å for residues 18--107, 245--417, and 439--514) ([@bib68]). The active site is well-resolved, except for one loop (residues 421--436). There is strong density in the both the IMP and NAD^+^ binding sites. We have modeled these ligands as IMP and NAD^+^, however because the enzyme filaments were actively turning over when flash frozen, we have likely captured a mixture of substrate-, intermediate-, and product-bound states. Attempts at focused classification of the active site to structurally isolate these states were unsuccessful.

The extended conformation is an ensemble of flexible states {#s2-3}
-----------------------------------------------------------

We resolved multiple conformations of filament segments in the ATP/IMP/NAD^+^ dataset ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). The most well-resolved was a D4-symmetric, fully extended octamer (3.3 Å, [Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1E--H](#fig3s1){ref-type="fig"}, [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). The eight Bateman domains are symmetrically extended with respect to their catalytic domains, giving the octameric segment a helical rise of 118 Å; a symmetric helix of these segments would have a twist of 36°. There is strong density at both of the canonical ATP-binding sites within the Bateman domain ([Figure 3F](#fig3){ref-type="fig"}), consistent with previous crystal structures of ATP/ADP-bound fungal and bacterial IMPDH ([@bib14]; [@bib43]).

We also resolved several bent filament segment structures, the best resolved of which reached 3.9 Å ([Figure 3G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1I--L](#fig3s1){ref-type="fig"}, [Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). This bent octamer contains two identical tetramers. For each, three protomers are in extended conformations, while one protomer is in the compressed conformation. Due to the symmetry of the octamer, the lone compressed protomer of each tetramer forms a Bateman domain dimer with an extended protomer of the opposing tetramer ([Figure 3H](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3D](#fig3s3){ref-type="fig"}). From each of the lower resolution ATP/IMP and ATP/NAD^+^ datasets, we also observed a single consensus filament assembly interface and many different filament segment classes, including fully extended and bent segments, as well as fully compressed segments ([Figure 3I--J](#fig3){ref-type="fig"}, [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}, [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}). To our knowledge, these are the first structure of IMPDH in the compressed conformation in the absence of guanine nucleotides. While the two canonical ATP sites are occupied, the third Bateman binding site (which forms only in the compressed state and is GTP/GDP-specific) remains unoccupied. This suggests that protomers within ATP-bound IMPDH filaments readily sample the compressed conformation, and that GTP binding to site 3 selectively stabilizes this state. Further, the ability of a compressed protomer to form a Bateman dimer with an extended partner demonstrates a lack of conformational cooperativity across the Bateman domain interface.

The balance of substrate and downstream product regulates filament assembly {#s2-4}
---------------------------------------------------------------------------

We and others previously reported that GTP can stabilize compressed IMPDH2 filaments or drive their disassembly, depending on what other ligands are present ([@bib5]; [@bib14]; [@bib22]). To understand how ligand status of the active site tunes the response to GTP, we systematically explored the effects of different ligand combinations on filament assembly. In the absence of substrate, GTP induces disassembly of filaments, but as little as 10 μM IMP inhibits disassembly ([Figure 4A--B](#fig4){ref-type="fig"}). Pre-treatment of filaments with IMP prevents disassembly by GTP, and addition of IMP promotes reassembly of filaments previously disassembled by GTP ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}).

![IMP and GTP allosterically modulate filament assembly and disassembly.\
(**A**) Roughly 2 mM GTP inhibits filament assembly of IMPDH by ATP. Negative stain EM, protein concentration 2 uM. Scale bar 100 nm. Final nucleotide concentrations for each EM grid were as indicated below each image. (**B**) Roughly 10 uM IMP inhibits filament assembly by GTP. Final nucleotide concentrations for each EM grid were as indicated below each image. (**C**) Composite cryo-EM density of the GTP/ATP/IMP filament assembly interface and fully compressed filament segment maps (20 mM GTP, 0.5 mM ATP, 1 mM IMP). (**D**) Cryo-EM density of the fully compressed filament end map. (**E**) Cryo-EM density of the GTP/ATP non-filament fully compressed free octamer map (2 mM GTP, 2 mM ATP). (**F--H**) Close-up ribbon views of the assembled and unassembled filament interfaces the maps in A-C. (**I**) Comparison between the tetramer conformations of the 'flat' assembled filament interface (green) and the 'bowed' unassembled free octamer (gray). (**J**) Cartoon of the relationship between tetramer bowing and filament assembly. (**K**) Model of the regulation of filament assembly by GTP and IMP.\
Figure 4---source data 1.Statistics of cryo-EM data collection, reconstruction and model refinement for the ATP, 2 mM GTP dataset.\
Figure 4---source data 2.Statistics of cryo-EM data collection, reconstruction and model refinement for the ATP/IMP, 20 mM GTP dataset.](elife-53243-fig4){#fig4}

To understand how IMP and GTP allosterically influence filament assembly and disassembly of ATP-bound IMPDH2, we acquired cryo-EM data of the enzyme in two ligand states: 1) ATP/GTP/IMP, and 2) ATP/GTP. To ensure morphological consistency, we sought to saturate the enzyme with GTP. For the ATP/GTP dataset, we used 2 mM GTP, which for both our initial negative stain experiments and cryo-EM preparations resulted in complete disassembly of filaments into free octamers ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). However, under saturating IMP concentrations, 2 mM GTP resulted in filaments that were often bent ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). This should not be possible if GTP were saturating all sites; our structures above suggest bent filaments must contain some extended protomers whose GTP-binding allosteric site 3 is disrupted. For the ATP/GTP/IMP cryo-EM dataset we therefore used a much higher GTP concentration (20 mM), which resulted in filaments with fully compressed segments ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). We explore this apparent difference in GTP affinity in more detail below.

The compressed filament dataset resulted in three high-resolution reconstructions: the consensus filament assembly interface, a fully compressed octameric filament segment, and a fully compressed octameric end segment ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). The ATP/GTP/IMP filament assembly interface map (3.0 Å) is identical (backbone RMSD = 0.407) to the ATP/IMP/NAD^+^ filament interface ([Figure 4---figure supplement 2B--C](#fig4s2){ref-type="fig"}, [Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}). Classifying the most well-resolved filament segments as before, we obtained a 3.2 Å structure of a fully compressed filament segment ([Figure 4C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2D--H](#fig4s2){ref-type="fig"}, [Figure 4---figure supplement 3B](#fig4s3){ref-type="fig"}). The Bateman domains are symmetrically compressed, with ligand density at all three allosteric sites. The active site is well resolved, including the canonical interactions between opposing active site fingers that inhibit catalysis by preventing catalytic dynamics ([@bib14]).

Compared to the uninhibited filament datasets, these GTP-saturated, +IMP filaments were shorter in length. As a result, in addition to filament segments, we identified many filament ends: octamers in which one tetramer does not have an assembled interface. The best-resolved structure of these filament ends (3.3 Å) is conformationally similar to the filament segments, being fully compressed, with well-resolved IMP-bound active sites in the inhibited conformation; however, without the filament assembly interface, the N-terminus is only partially resolved ([Figure 4D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2I--L](#fig4s2){ref-type="fig"}, [Figure 4---figure supplement 3C](#fig4s3){ref-type="fig"}).

From the free octamer dataset containing ATP/GTP, we used a similar symmetry-expansion and classification strategy to that used for the filament datasets ([Figure 4---figure supplement 4A](#fig4s4){ref-type="fig"}). This scheme confirmed that virtually all the particles were symmetric, fully compressed free octamers in which both potential filament assembly interfaces are unbound, with some poorly resolved minority classes of larger oligomers ([Figure 4---figure supplement 4B--C](#fig4s4){ref-type="fig"}). The best resolved free octamer class reached intermediate resolution (4.5 Å) ([Figure 4E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 4D--F](#fig4s4){ref-type="fig"}, [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}, [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). This octamer is conformationally similar (backbone RMSD = 0.978 Å) to a recent higher-resolution crystal structure of IMPDH2 bound to GTP (PDB 6i0o) ([@bib14]; [@bib25]). The Bateman domains are fully compressed with three occupied allosteric sites. Without IMP present, the active site loops of the free octamers are disordered, with partial density for the fingers extending across to the opposing tetramer.

Whether in a filament segment, filament end, or free octamer, the Bateman domains of the three ATP/GTP-bound IMPDH octamer types are fully compressed, with ligand density in all regulatory sites including the critical GTP/GDP-specific third site, which 'staples' IMPDH octamers in the fully compressed, inhibited conformation. But we observed two key structural differences that correlated with assembly state: the conformation of the N-terminus, and the relative orientation of protomers within each tetramer. The filament interface of the inhibited segments is unchanged from the uninhibited filaments ([Figure 4F](#fig4){ref-type="fig"}). However, at the free filament ends the N-terminus is only partially unresolved (a.a. 1--11), with the resolvable portion rotated \~30° degrees compared to the bound interface, such that Val13 inserts into the shallow hydrophobic pocket formed by A307, A308, and Lys311 of the neighboring protomer, very similar to its position in the GTP-bound free octamer crystal structure (PDB 6i0o) ([Figure 4G](#fig4){ref-type="fig"}) ([@bib25]). The resolution of the free octamer structure precludes side chain placement, but the backbone density of the unbound N-terminus is in the same position, indicating that free filament ends and free octamers are in the same conformation ([Figure 4H](#fig4){ref-type="fig"}).

We noticed a striking difference between the conformation of the catalytic core assembly in free versus assembled states. Each protomer of the free octamer and at filament ends is tilted \~5° relative to the four-fold symmetry axis, such that the tetramer becomes more 'bowed' than the 'flat' tetramers at filament assembly interfaces ([Figure 4I](#fig4){ref-type="fig"}, [Video 1](#video1){ref-type="video"}). The tetramers found in the GTP-bound free octamer crystal structure (PDB 6i0o) are in a similar bowed conformation ([@bib25]). The bowed tetramer conformation and the filament assembly interface are mutually exclusive. When the N-terminus conformation from the free octamer is modeled into the flat tetramer of the filament assembly interface, V13 is not correctly positioned to bind the A307/A308/K311 of the neighboring protomer, and instead clashes with K311 and A307 ([Figure 4---figure supplement 6A](#fig4s6){ref-type="fig"}). Thus the flat conformation promotes release of the N-termini from their binding sites on neighboring protomers, freeing them to rotate into the conformation seen in the assembled filament interface. The reciprocal operation is also not possible; for a bowed tetramer modeled with the N-terminus conformation from the filaments, only one protomer at a time can form the assembled interface ([Figure 4---figure supplement 6B](#fig4s6){ref-type="fig"}). The other N-termini are out of position, with significant separation of the critical residues Y12 and R356 as well as multiple steric clashes. Thus bowed tetramers cannot form the IMPDH2 filament assembly interface, and tetramer flattening is a necessary precondition for IMPDH2 filament assembly ([Figure 4J](#fig4){ref-type="fig"}).

###### Comparison between the 'flat' tetramer of assembled filaments and the 'bowed' tetramer of free octamers.

Morph comparison between catalytic tetramers of the GTP/ATP/IMP filament assembly interface and the GTP/ATP free octamer. For visualization purposes, we have depicted the complete N-terminus in both conformations, however in the free octamer model, some residues were unresolved (gray). For both models, opposing tetramers, Bateman domains, and active site loops have been hidden from view.

These three structures of inhibited IMPDH2 conformations provide a model by which filament assembly is influenced by IMP and GTP through tetramer bowing and flattening ([Figure 4K](#fig4){ref-type="fig"}). In the absence of substrate, GTP induces both compression of filament segments and tetramer bowing, with the latter resulting in filament disassembly. But when IMP is bound, the disordered active site loops become ordered and rigid, buttressing intra-tetramer contacts as well as forming a pseudo-beta-barrel between opposing tetramers in the GTP-bound state. These increased contacts work to resist tetramer bowing and more readily sample the flat tetramer conformation, which promotes, and is stabilized by, the filament assembly interface. When IMP levels are low, GTP promotes filament disassembly, but high IMP levels shift the equilibrium towards filament assembly.

IMPDH2 filaments resist GTP inhibition {#s2-5}
--------------------------------------

Based on this model, during quiescence, when the salvage pathways supply ample GTP and IMP production is downregulated, intracellular IMPDH2 will be in the fully compressed, fully inhibited, ATP/GTP-bound free octamer state. Without increased IMP production, guanine depletion will result in transient octamer extension and filament assembly, both of which will reverse as the resulting increase in IMPDH flux restores guanine levels by diverting substrate from the parallel de novo adenine pathway, mirroring the extension/compression behavior of non-filament assembling homologues ([@bib14]; [@bib25]). Recently, it was shown that in vivo IMPDH assembly is promoted by increases in intracellular IMP ([@bib40]). We therefore reasoned that the primary regulatory function of filament assembly may apply only in the proliferative state, when intracellular IMP levels are upregulated, preventing filament disassembly by GTP.

To probe whether filament assembly influences the regulatory effects of GTP on IMPDH2 activity we compared enzyme kinetics of the wildtype enzyme with the non-assembling mutant Y12A. We measured the GTP dose-response of IMPDH2 pre-incubated with varying levels of ATP, and found that wild-type enzyme is less sensitive to GTP inhibition, compared with Y12A ([Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}). Depending on ATP concentration, the apparent GTP IC50 of the wild-type was roughly two-fold lower than for Y12A. At higher ATP levels, the apparent GTP IC50 of WT and the non-assembly mutant both increase. We attribute this to competition between ATP and GTP at the first and second Bateman sites, suggesting that independent of filament assembly, GTP inhibition of IMPDH2 is affected by ATP. Notably, the range of GTP in which the substrate-saturated filaments resist GTP inhibition is within the upper range of in vivo concentrations ([@bib75]). One function, then, of IMPDH2 filaments is to resist inhibition by GTP.

To correlate structural differences in IMPDH2 filaments as a function of GTP concentration, we collected negative stain EM data directly from three reaction volumes used for the GTP inhibition experiments, corresponding to uninhibited filaments (no GTP),\~10% inhibited filaments (2.5 mM GTP), and fully inhibited filaments (20 mM GTP) ([Figure 5A](#fig5){ref-type="fig"}). As in the cryo-EM datasets, we found that uninhibited filaments were often extended, and fully inhibited filaments were universally compressed. However, we noted that the partially inhibited filaments contained a more heterogeneous mix of extended, bent, and compressed segments.

![IMPDH2 filaments resist GTP inhibition by promoting bent octamer conformations that separate opposing active sites.\
(**A**) Negatively stained EM of uninhibited (left), partially inhibited (center), and fully inhibited (right) IMPDH2. Representative micrographs and reference free 2D class averages. Prepared with 1 mM IMP, 1 mM NAD^+^, and either 0, 2.5 mM, or 20 mM GTP. (**B--C**) NAD+ saturation curves of uninhibited WT IMPDH2 (solid line), and the non-assembly mutant Y12A (dashed line). Reactions performed with 0.5 mM ATP, 1 mM IMP, and varying NAD^+^. (**C**) NAD+ saturation curves of WT filaments treated with 0.5 mM ATP, 1 mM IMP, varying NAD^+^ and 2 mM GTP. (**D**) Six cryo-EM maps from two datasets (uninhibited ATP/IMP/NAD+ and partially inhibited ATP/IMP/NAD+/\[2 mM\]GTP) exhibiting a range of Bateman domain conformations. The uninhibited filaments were prepared with 0.5 mM ATP, 2 mM IMP, and 2 mM NAD^+^. The partially inhibited filaments were prepared with 0.5 mM ATP, 2 mM IMP, and 2 mM NAD^+^, and 2 mM GTP. (**E**) A view of a single tetramer from the inside of each octamer. The lighter colored tetramer from panel A is hidden, with the surface area buried between tetramer active sites colored in yellow, with the indicated total buried surface area. (**F**) Corresponding views of Bateman domain conformations. Protein displayed as ribbon, with the two interacting Bateman domains colored orchid and light pink. Cryo-EM density for non-protein ligand densities is colored green and red, for ATP and GTP, respectively. Symmetry identities labeled with gray letters. In the extended conformation, allosteric site 3 is distorted, and does not bind ligands (black dashes). Allosteric site 3 is formed in compressed protomers, but in the absence of guanine nucleotides it remains unoccupied (black asterisk). In the extended protomers of some bent octamers, is is possbile that allosteric site 2 is only partially occupied (black tilde).\
Figure 5---source data 1.Statistics of cryo-EM data collection, reconstruction and model refinement for the ATP/IMP/NAD^+^, 2 mM GTP dataset.](elife-53243-fig5){#fig5}

Next, we compared NAD^+^ kinetics of uninhibited (0 mM GTP) and partially inhibited (2 mM GTP) filaments with saturating IMP concentrations ([Figure 5B--C](#fig5){ref-type="fig"}). As expected, in the absence of GTP WT and the non-assembling mutant have similar apparent Michaelis-Menten kinetics ([@bib5]). Inhibition of WT by this concentration of GTP is partial and non-competitive. In contrast, the non-assembling mutant is strongly inhibited. In the absence of saturating IMP, these same GTP levels result in complete octamer compression and filament disassembly, providing a possible mechanism by which filament assembly alters GTP inhibition: by resisting the fully compressed state.

To better understand this partially inhibited state, we collected cryo-EM data of IMPDH2 with saturating substrates, 0.5 mM ATP, and 2 mM GTP ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). Under these conditions, we observed the non-assembly mutant Y12A was 84% inhibited but WT enzyme was only 16% inhibited. We resolved structures of not only the filament assembly interface and several distinct filament segments, but surprisingly, two different free octamers; a canonical free octamer (a dimer of tetramers bound by Bateman domains), and also a small class of free interfacial octamers (a dimer of tetramers bound by the filament assembly interface) ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}).

The 3.1 Å resolution consensus assembly interface map is identical to the uninhibited and fully inhibited consensus interfaces, including a well-resolved active site with strong density for both substrates; as with the ATP/IMP/NAD+ structures these filaments are actively turning over and we have likely captured many states, which we have modeled simply as IMP/NAD^+^ ([Figure 5---figure supplement 2B--C](#fig5s2){ref-type="fig"}, [Figure 5---figure supplement 5A](#fig5s5){ref-type="fig"}, [Figure 5---figure supplement 7A](#fig5s7){ref-type="fig"}). As expected, the filament segments exhibited a range of conformations ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}). The best resolved of these were a fully compressed filament segment at 3.4 Å resolution, and two bent conformations at 4.2 and 3.7 Å resolution ([Figure 5---figure supplement 2E--M](#fig5s2){ref-type="fig"}, [Figure 5---figure supplement 5B--D](#fig5s5){ref-type="fig"}). The fully compressed filament segment is identical to the corresponding structure from the inhibited (20 mM GTP) filament dataset, with all Bateman binding sites occupied ([Figure 5---figure supplement 7B](#fig5s7){ref-type="fig"}). As with the bent conformation from the ATP/IMP/NAD^+^ dataset, the two bent filament segments are each two-fold symmetric octamers of asymmetric tetramers containing different proportions of extended or compressed protomers ([Figure 5---figure supplement 7C--D](#fig5s7){ref-type="fig"}). The asymmetric unit from one of these bent segments is a tetramer with two compressed and two extended protomers, and the other has three compressed and one extended. For each of the compressed protomers, there is clear ligand density bound at Bateman Site 3; for the extended protomers this site is unformed and empty.

Unlike the mixture of extended and compressed protomers we observed in the filaments, the free canonical octamers were universally compressed ([Figure 5---figure supplement 3A--C](#fig5s3){ref-type="fig"}). As with the ATP/GTP free octamer, the best resolved canonical free octamer class (3.8 Å) is fully compressed and bowed, despite having both substrate sites occupied ([Figure 5---figure supplement 3D--F](#fig5s3){ref-type="fig"}, [Figure 5---figure supplement 6A](#fig5s6){ref-type="fig"}, [Figure 5---figure supplement 7E](#fig5s7){ref-type="fig"}). Thus, even in the IMP-bound state, the compressed/flat conformation is less preferred, unless stabilized by the filament assembly interface. The small class of free interfacial octamers (3.8 Å) was no different from the filament interface maps, except that the Bateman domains are completely unresolved, indicating that without the stabilization provided by Bateman domain dimerization, these regions are highly flexible ([Figure 5---figure supplement 4A--F](#fig5s4){ref-type="fig"}, [Figure 5---figure supplement 6B](#fig5s6){ref-type="fig"}, [Figure 5---figure supplement 7F](#fig5s7){ref-type="fig"}). The observation of dramatically different structural ensembles in filament-bound and free IMPDH2, in the presence of identical ligand concentrations, explains the role of filament assembly in resisting compression and GTP inhibition.

Filament-specific IMPDH2 conformations reduce GTP affinity and promote activity {#s2-6}
-------------------------------------------------------------------------------

From our different cryo-EM datasets combined, we have now determined structures of canonical IMPDH2 octamers bound to allosteric effectors and both substrates, in six distinct conformations ([Figure 5D](#fig5){ref-type="fig"}). From the uninhibited ATP/IMP/NAD^+^ dataset we resolved a fully extended filament segment, and a bent segment in which for each tetramer, 3 protomers were extended and 1 was compressed. From the partially inhibited GTP/ATP/IMP/NAD^+^ dataset, we resolved 2:2, 3:1, and fully compressed filament segments, and a fully compressed free octamer. These five structures provide a mechanism by which the Bateman domain extension of discrete protomers promoted by filament assembly resists GTP inhibition ([Figure 5E](#fig5){ref-type="fig"}). Depending on the degree of extension/bending/compression, filament segments exhibit a range of increasingly stronger interactions between opposing catalytic domains. For the fully extended segments, there are no interactions, and the flexible active loops are able to perform the complex conformational changes necessary for catalysis ([@bib14]; [@bib30]). Going through the progressively more compressed bent states, there is progressively greater surface area buried by a series of distinct contacts between the opposing active site loops, until the fully compressed filament segment. For the active sites that make these contacts, activity is likely impaired because the active site loops are constrained. However, the presence of some unconstrained active sites in the bent filament segments means that these protomers are catalytically active. This effect is not cooperative within the octamers, and even a single extended protomer is sufficient to reduce inhibitory active site contacts.

The Bateman domain ligand occupancy of these five filament segment conformations varies significantly. Given the resolution range of these structures (3--4 Å) it is not possible to unequivocally distinguish ATP from GTP, and we have assigned ligand identity according to previous structures of a bacterial IMPDH bound to ATP (PDB 4dqw) ([@bib43]) and a fungal IMPDH bound to ATP and GDP (PDB 5tc3) ([@bib14]). These were chosen due to conformational similarity of the Bateman domains of these structures to our ATP/IMP/NAD^+^ fully extended and ATP/IMP/GTP fully compressed human filament cryo-EM structures; backbone RMSDs were 1.163 and 0.856 Å, respectively (for residues corresponding to human IMPDH2 residues 110--244). As previously described, in both the fully extended and 1:3 compressed:extended segments there is clear ligand density at Bateman sites 1 and 2 ([Figure 5F](#fig5){ref-type="fig"}). For the single compressed protomer in the latter, site 3 is formed but due to the absence of GTP in that dataset it is unoccupied. In the partially inhibited filament dataset, for which the buffer contained both ATP and GTP, we see a greater variation in Bateman ligand occupancy. For the 2:2 compressed:extended segment, there is full occupancy at sites 1, 2, and 3 in the compressed protomers, however for the two extended protomers there is strong density at site 1 and partial density at site 2. The 3:1 compressed:extended segment is qualitatively similar; the three compressed protomers possess full ligand occupancy but for the one extended protomer site 2 has only partial density. For both the fully compressed filament segment and the free octamer there is full ligand density. Thus filament assembly promotes the extended state of individual protomers, which reduces overall GTP affinity due to disruption of site 3.

To probe whether the conformations of filament segments co-vary along the length of the filaments, we subjected the five filament-interface cryo-EM datasets presented here to classification against a series of synthetic templates with different conformations, and compared the conformations of interfaced octamers through calculations of odds ratios ([Figure 5---figure supplements 8](#fig5s8){ref-type="fig"}--[13](#fig5s13){ref-type="fig"}). The results of the classification against synthetic templates are in line with the experimentally derived classifications for each dataset, but we did not find a strong correlation in segment conformation along filaments, suggesting that conformational changes are not cooperative across the filament interface.

Discussion {#s3}
==========

Understanding the complex ways cells regulate IMPDH activity to efficiently maintain spatiotemporal control of nucleotide levels in response to varying demand has direct implications for human health. IMPDH activity is upregulated to increase guanine levels in proliferating tissues like tumors and regenerating liver ([@bib29]; [@bib31]; [@bib50]; [@bib76]; [@bib81]). IMPDH plays a particularly important role in the immune response, where T-cell activation is dependant on increased production of purine nucleotides, and is associated with IMPDH filament assembly ([@bib16]; [@bib22]; [@bib26]; [@bib85]). As a result, IMPDH is the target of several drugs used in immunosuppressive treatment of both autoimmune disease and organ transplant rejection, and is considered a promising target for antineoplastic agents ([@bib11]; [@bib45]; [@bib67]).

Assembly and disassembly of IMPDH into filaments has been observed in healthy proliferative cells, and in cancer cells ([@bib40]; [@bib80]). IMPDH filaments reversibly assemble in stimulated T-cells as they transition to a proliferative state, in a mechanism dependent on multiple metabolic signaling pathways and on the levels of guanine nucleotides ([@bib16]; [@bib22]). Despite the importance of understanding human IMPDH regulation, until now the regulatory role of IMPDH filament assembly has not been explored at the structural level.

We propose a model that describes the regulatory role of human IMPDH2 filament assembly, in which assembly reduces feedback inhibition of enzyme activity in a substrate-dependant manner, increasing flux through the de novo guanine nucleotide synthesis pathway in response to proliferative signaling. In the absence of either IMP or guanine ligands, IMPDH2 is conformationally dynamic ([Figure 6A](#fig6){ref-type="fig"}). Apo IMPDH2 forms stable tetramers, which freely sample both the 'bowed' and 'flat' tetramer conformations, with the latter resulting in release of the N-terminus and assembly into stable interfacial octamers. Adenine nucleotides bind with high affinity to the Bateman domain, resulting in stable filaments in which the active site loops remain unconstrained and the enzyme is active. The ATP concentration required to induce filament assembly in vitro is far below the expected in vivo levels; we thus predict the apo state to be rare in human cells ([@bib75]). Without bound guanine nucleotides, the Bateman domains of individual protomers freely compress and extend ([Figure 6B](#fig6){ref-type="fig"}). However, the flat tetramer conformation found in assembled IMPDH2 filaments is resistant to full compression of octameric filament segments. Binding of GTP to the Bateman domain stabilizes the compressed state, leading to lattice strain that is relieved by disassembly of the filament interface and tetramer bowing. In this way high intracellular guanine levels disassemble IMPDH2 filaments into stable free octamers whose activity is inhibited. Binding of IMP to the active site stabilizes the flexible active site loops, and saturation with both IMP and GTP results in compressed filaments in which the active sites of opposing tetramers interlock into a stable network. This rigidifies the octameric filament segment, which now resists the lattice strain brought on by compression, blocking GTP-induced filament disassembly.

![Model of IMPDH2 assembly and filaments' role in guanine nucleotide regulation.\
(**A**) Filament assemble when octamer interactions are stabilized by ATP binding to the regulatory domain (pink), and the N-terminal residues (blue) are released by flattening of the catalytic tetramer (green). Filament assembly interactions stabilize the flat conformation. (**B**) GTP binding stabilizes an inhibited, compressed conformation. Filament is less sensitive to GTP-induced compression, maintaining a population of octamers in mixed activity states. Filaments in the fully compressed GTP-bound state are strained, which promotes disassembly that is inhibited by substrate IMP binding. (**C**) The equilibrium in (**B**) explains the different cellular conditions in which IMPDH polymerization occurs. (i) Under homeostatic conditions IMPDH2 is dispersed and activity is regulated by GTP binding to octamers, which balances low levels of de novo synthesis between adenine and guanine pathways. ii) When guanine nucleotides are depleted the equilibrium shifts toward filaments. iii) Proliferative signaling can directly shift the equilibrium toward filaments, where higher flux is maintained through the guanine pathway under elevated GTP concentrations due to reduced sensitivity of the filaments to GTP inhibition (dashed line).](elife-53243-fig6){#fig6}

By balancing these complex conformational dynamics, cells fine-tune feedback inhibition of the enzyme, consistent with the states in which IMPDH filaments are observed in cells ([Figure 6C](#fig6){ref-type="fig"}). Under homeostatic conditions, the salvage pathways provide sufficient purine nucleotides, and IMP production is low. Under these conditions IMPDH2 is bound to both adenine and guanine nucleotides, but not IMP, forming free octamers rather than filaments. In vivo, filaments are typically not observed in quiescent cells; rather, as in our model, their assembly is associated with increased intracellular IMP and decreased intracellular GTP ([@bib15]; [@bib38]; [@bib40]; [@bib63]). Depletion of guanine allows Bateman domain extension, and transient assembly into enzymatically active filaments. However, upon restoration of guanine levels, these active filaments disassemble into compressed free octamers, mirroring the known feedback inhibition behavior of non-filament forming IMPDH homologues ([@bib14]; [@bib13]; [@bib25]).

The key difference is the substrate dependance of IMPDH2 filament assembly. IMP-saturated IMPDH2 filaments resist both disassembly and the fully compressed, inhibited state. Even at elevated guanine nucleotide levels, these filaments retain a proportion of uninhibited active sites. This allows the cell to modulate enzyme activity to balance levels of product and substrate in response to metabolic demand, which can vary significantly depending on cell type and cell cycle stage. Our data strongly support the idea that IMPDH2 filament assembly serves to elevate intracellular guanine nucleotide levels during the proliferative state by resisting feedback inhibition. Production of IMP is upregulated in response to overall purine demand, as well as in response to proliferative signaling via the mechanistic target of rapamycin (mTOR) ([@bib10]; [@bib69]). Inhibition of mTOR reverses IMPDH filament assembly in activated mouse T-cells, as well as proliferating mouse liver cells ([@bib19]; [@bib22]). Thus the dependence of filament assembly on IMP levels provides an avenue for regulation of assembly through established proliferative signaling pathways.

Many metabolic enzymes form filamentous polymers in cells in response to changes in metabolic state ([@bib34]; [@bib51]; [@bib53]; [@bib55]; [@bib58]; [@bib61]; [@bib66]; [@bib83]). Most of these metabolic filaments are assembled from important regulatory enzymes, which suggests polymerization may play a role in modulating flux through these pathways. Recently, in just a few cases, structural and biochemical studies have provided insight into the functional consequences of enzyme filament assembly, suggesting that one role of polymers is to regulate activity by locking enzymes into active or inactive conformations through assembly contacts ([@bib8]; [@bib32]; [@bib46]; [@bib70]; [@bib78]). Thus, it was surprising when our initial characterization of IMPDH2 filaments showed that assembly did not affect enzymatic activity or the ability to switch between active or inactive conformations ([@bib5]). Instead, as we have shown here, IMPDH2 filaments fine-tune the the allosteric response by reducing affinity for inhibitory downstream products. This represents a new way in which enzyme self-assembly can modulate flux through metabolic pathways, providing an additional layer of regulatory control on top of existing transcriptional, post-translational, and allosteric regulation.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                   Designation                                         Source or\                                       Identifiers   Additional\
  (species) or\                                                                                       reference                                                      information
  resource                                                                                                                                                           
  ----------------------------------------------- --------------------------------------------------- ------------------------------------------------ ------------- ----------------------------
  Strain, strain background (*Eschericia coli*)   BL21(DE3)                                           Thermo Scientific                                EC0114        competent cells

  Recombinant DNA reagent                         pSMT3-hIMPDH2-WT (pJK053)                           <https://doi.org/10.1091/mbc.E17-04-0263>                      expression plasmid

  Recombinant DNA reagent                         pSMT3-hIMPDH2-Y12A (pJK061)                         <https://doi.org/10.1091/mbc.E17-04-0263>                      expression plasmid

  Peptide, recombinant protein                    Ubiquitin-like-specific protease 1 (ULP1)           <https://doi.org/10.1091/mbc.E17-04-0263>                      purified in house

  Peptide, recombinant protein                    human IMPDH2                                        <https://doi.org/10.1091/mbc.E17-04-0263>                      purified in house

  Chemical compound, drug                         LB broth mix                                        LabExpress                                       3003          bacterial growth media

  Chemical compound, drug                         IPTG                                                GoldBio                                          I2481C100     

  Chemical compound, drug                         MgCl2                                               Fisher Scientific                                BP215-500     

  Chemical compound, drug                         KPO4                                                Fisher Scientific                                BP362-500     

  Chemical compound, drug                         KCl                                                 Fisher Scientific                                BP217-3       

  Chemical compound, drug                         imidazole                                           Sigma Aldrich                                    SLBT7469      

  Chemical compound, drug                         urea                                                Fisher Scientific                                BP169-212     

  Chemical compound, drug                         DTT                                                 Fisher Scientific                                172--25       

  Chemical compound, drug                         HEPES                                               Fisher Scientific                                BP310-1       

  Chemical compound, drug                         ATP                                                 Sigma Aldrich                                    A2383-10G     

  Chemical compound, drug                         GTP                                                 Sigma Aldrich                                    G8877-1G      

  Chemical compound, drug                         IMP                                                 Sigma Aldrich                                    57510--5G     

  Chemical compound, drug                         NAD+                                                Sigma Aldrich                                    N6522-1G      

  Chemical compound, drug                         uranyl formate                                      Electron Microscopy Sciences                     22450         negative stain EM

  Software, algorithm                             GCTF                                                <https://doi.org/10.1016/j.jsb.2015.11.003>                    

  Software, algorithm                             Relion                                              <https://doi.org/10.7554/eLife.42166>                          

  Software, algorithm                             MotionCor2                                          <https://doi.org/10.1038/nmeth.4193>                           

  Software, algorithm                             SWISS-MODEL                                         <https://doi.org/10.1093/nar/gky427>                           

  Software, algorithm                             UCSF Chimera                                        <https://doi.org/10.1002/jcc.20084>                            

  Software, algorithm                             COOT                                                <https://doi.org/10.1107/S0907444910007493>                    

  Software, algorithm                             PHENIX                                              <https://doi.org/10.1107/97809553602060000865>                 

  Software, algorithm                             LocScale                                            <https://doi.org/10.7554/eLife.27131>                          

  Software, algorithm                             Molprobity                                          <https://doi.org/10.1107/S0907444909042073>                    

  Software, algorithm                             EMRinger                                            <https://doi.org/10.1038/nmeth.3541>                           

  Other                                           C-flat 2/2 holey carbon films on Cu 200 mesh grid   Protochips, Inc                                  CF-2/2--2C    cryo-EM sample preparation

  Other                                           HisTrap FF Crude 5 ml                               GE Life Sciences                                 17528601      protein purification

  Other                                           Superose 6 Increase 10/300 GL                       GE Life Sciences                                 29-0916-96    protein purification

  Other                                           Amicon Ulta-15 30K MWCO centrifugal filters         Millipore                                        UFC903008     protein concentration
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Recombinant IMPDH expression and purification {#s4-1}
---------------------------------------------

Purified hIMPDH2 was prepared as described previously ([@bib5]). BL21 (DE3) *E. coli* transformed with a pSMT3-Kan vector expressing N-terminal SMT3/SUMO-tagged hIMPDH2 were cultured in Luria broth at 37°C until reaching an OD~600~ of 0.8 and then induced with 1 mM IPTG for 4 hr at 30°C and pelleted. The remainder of purification was performed at 4°C. Pellets were resuspended in lysis buffer (50 mM KPO4, 300 mM KCl, 20 mM imidazole, 800 mM urea, pH 8) and lysed with an Emulsiflex-05 homogenizer. Lysate was cleared by centrifugation and SUMO-tagged hIMPDH2 chromatagraphically purified with HisTrap FF columns (GE Healthcare Life Sciences) and an Äkta Start chromatography system. After in-column washing with lysis buffer and elution (with 50 mM KPO4, 300 mM KCl, 500 mM imidazole, pH 8), peak fractions were treated with 1 mg ULP 1 protease ([@bib49]) per 100 mg hIMPDH2 for 1 hr, followed by the addition of 1 mM dithiothreitol (DTT) and 800 mM urea. Protein was then concentrated using a 30,000 MWCO Amicon filter and subjected to size-exclusion chromatography using Äkta Pure system and a Superose 6 column pre-equilibrated in filtration buffer (20 mM HEPES, 100 mM KCl, 800 mM urea, 1 mM DTT, pH 8). Peak fractions were flash-frozen in liquid nitrogen and stored at −80°C.

IMPDH assembly {#s4-2}
--------------

Filaments (or, depending on ligand state, free octamers) were prepared by diluting aliquots of purified hIMPDH2 in activity buffer (20 mM HEPES, 100 mM KCl, 1 mM DTT, pH 7.5) to 2 μM in the presence of varying concentrations of ATP, GTP, IMP, and/or NAD^+^ and incubating for 30 min at 20°C. Nucleotide stocks were prepared using ATP disodium salt hydrate (Sigma A2383), GTP sodium salt hydrate (Sigma G8877), IMP disodium salt hydrate (Acros AC226260050), and β-Nicotinamide adenine dinucleotide hydrate (Sigma N6522), For all buffers, protein preparations, and nucleotide stocks, final pH was checked and titrated if necessary to 7.5 with KOH or HCl.

IMPDH activity assays {#s4-3}
---------------------

Protein aliquots were diluted in activity buffer and pre-treated with varying concentrations of ATP, GTP, and IMP for 30 min at 20°C, in 96 well UV transparent plates (Corning model 3635). Reactions (100 uL total) were initiated by addition of varying concentrations of NAD^+^. NADH production was measured by optical absorbance (340 nm) in real-time using a Varioskan Lux microplate reader (Thermo Scientific) at 20°C, 1 measurement/min, for 20 min; absorbance was correlated with NADH concentration using a standard curve. Specific activity was calculated by linear interpretation of the reaction slope for a 5 min window beginning 3 min after reaction initiation.

Negatively stained electron microscopy {#s4-4}
--------------------------------------

Protein preparations were applied to glow-discharged continuous carbon EM grids and negatively stained with 2% uranyl formate. Grids were imaged by transmission electron microscopy using an FEI Tecnai G2 Spirit at 120kV acceleration voltage and a Gatan Ultrascan 4000 CCD using the Leginon software package ([@bib71]). Micrographs were collected at a nominal 67,000x magnification (pixel size 1.6 Å). GCTF was used for contrast transfer function (CTF) estimation, and Relion for particle picking and 2D classification ([@bib62]; [@bib82]; [@bib86]).

Electron cryo-microscopy sample preparation and data collection {#s4-5}
---------------------------------------------------------------

Protein preparations were applied to glow-discharged C-flat holey carbon EM grids (Protochips), blotted, and plunge-frozen in liquid ethane using an Vitrobot plunging apparatus (FEI) at 20°C, 100% relative humidity. High-throughput data collection was performed using an FEI Titan Krios transmission electron microscope operating at 300 kV and equipped with a Gatan image filter (GIF) and post-GIF Gatan K2 Summit direct electron detector using the Leginon software package ([@bib71]). For the two datasets with non-filament octamers of IMPDH, which exhibit a preferred orientation, it was necessary to collect images with the stage tilted in order to capture a sufficient range of views for 3D reconstruction ([Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}, [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}).

Electron cryo-microscopy image processing {#s4-6}
-----------------------------------------

Movies were collected in super-resolution mode, then aligned and corrected for beam-induced motion using Motioncor2, with 2X Fourier binning and dose compensation applied during motion correction ([@bib71]; [@bib84]). CTF was estimated using GCTF ([@bib82]). Relion 3.0 was used for all subsequent image processing ([@bib82]; [@bib86]). Although multiple datasets of hIMPDH2 under the different ligand states were collected, each dataset was individually processed using approximately the same overall pipeline ([Figure 2---figure supplement 1E--G](#fig2s1){ref-type="fig"}), with some variations from dataset to dataset ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}, [Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). First, for each dataset, autopicking templates and initial 3D references maps were prepared by manually picking and extracting boxed particles from a small subset of micrographs, and classifying/refining in 2D and 3D. For these initial 3D refinements, a featureless, soft-edged cylinder was used as a refinement template of filaments, and a previously published cryo-em map (EMDB-8692) was used as template for non-filament octamers ([@bib5]). Because IMPDH filament segments possess D4 point-group symmetry, two different locations along filaments may be used as symmetry origins: the centers of canonical octamer segments, or the centers of the assembly interface between segments. For the filament datasets, we prepared and used auto-picking templates centered on the filament assembly interface. For the datasets containing non-filament octamers of hIMPDH2, auto-picking templates centered on these non-filament particles were also included. Due to the flexibility of hIMPDH2 filaments, helical segments were processed as single particles, and at no point was helical symmetry applied during image processing. After template-based autopicking of each complete dataset, picked particles were boxed and extracted from micrographs, and subjected to hierarchical 2D classification to select the best-resolved classes. These selected particles were then auto-refined in 3D as a single class with symmetry applied (D4 for filament segments and free octamers, C4 for filament ends). Exploratory image processing of the assembly interface-centered filament reconstructions made it apparent that the eight catalytic domains surrounding this interface appeared conformationally homogenous, while the Bateman domains and neighboring octamers appeared conformationally varied. Additionally, due to the flexibility of the filaments, and the tendency of filament ends to adhere to the air-water interface, many filaments were tilted out of plane, with neighboring segments overlapping in projection.

To improve resolution, partial signal subtraction was performed at this stage, using a mask that left only the central eight catalytic domains of the filament assembly interface, subtracting the poorly resolved Bateman domains and neighboring segments, which served to improve resolution after subsequent auto-refinement. Per-particle defocus and per-micrograph astigmatism were then optimized using CTF refinement, which improved resolution further. The resulting consensus refinements of the filament assembly interfaces were well-resolved, however data on Bateman domain conformation was missing, with these regions very poorly resolved when subtracted regions were restored to the reconstructions by reversion to original non-subtracted particles (data not shown). To resolve the different Bateman domain conformations, we applied particle symmetry expansion (D4 to C1) and classified particles without additional alignment. Because at this stage the reconstructions were centered on the filament assembly interface, each boxed 'particle' contained elements of two different neighboring octamers. The potential conformational space was reduced by applying a mask enclosing only one of these two octamers. By hierarchical focused classification of the off-origin octamers we were able to classify multiple conformations of the octameric filament segments, as well as incomplete segments and filament ends. Symmetry expansion was also applied to the non-filament octamer datasets, with a mask including the entire particle, which allowed classification of the most symmetric and well-resolved classes. To further improve resolution of the varying symmetry-expanded segment classes, the reconstruction symmetry origins were moved from the filament assembly interface to the canonical octamers by re-extraction with re-centering. For each class, symmetry was then collapsed by removing redundant overlapping particles, Euler angles reset to zero. After auto-refining once again, we observed that the most well-resolved octameric segments from the asymmetric symmetry-expanded classifications exhibited some apparent symmetry, with fully extended or fully compressed octamers appearing D4 symmetric, and some bent classes apparently D1 symmetric. We therefore applied these symmetries during subsequent refinement and classification of these new octamer-centered classes. As before, signal subtraction of neighboring filament segments improved resolution considerably. Additional rounds of CTF refinement and 3D classification identified the best-resolved particles from each of these conformational classes. Final overall resolution (according to the FSC = 0.143 criterion), as well as local resolution, was assessed using Relion postprocessing.

Model building and refinement {#s4-7}
-----------------------------

As initial templates for model building, two hybrid models (representing hIMPDH2 in either an extended or compressed state) were prepared by combining elements from existing crystal structures. For both templates, the catalytic domain and substrate poses (residues 18--107, and 245--514) were taken from a crystal structure of an inhibitor-bound hIMPDH2 (PDB 1nf7), and the Bateman domains and ligand poses (residues 108--244) were based on fungal (*A. gossypii)* IMPDH crystallized in either the extended or compressed states (PDB 5mcp and 5tc3, respectively), and SWISS-MODEL homology modeling ([@bib14]; [@bib68]; [@bib77]). The N-terminus (residues 1--17) were modeled by hand. In all maps, a single active site loop (residues 421 to 436) was unresolved, and these residues were not modeled. After rigid-body fitting of templates into the cryo-EM densities using UCSF Chimera, repeated cycles of manual fitting with Coot, automated fitting with phenix.real_space_refine (employing rigid-body refinement, NCS constraints, gradient-driven minimization and simulated annealing) and local B-factor sharpening of cryo-EM data via LocScale were used for final atomic model refinement and local sharpening of cryo-EM maps ([@bib1]; [@bib23]; [@bib36]; [@bib59]). Final models were evaluated with MOLPROBITY and EMRinger ([@bib7]; [@bib20]). Data collection parameters and refinement statistics are summarized in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}, [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}, [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}, [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}. Figures were prepared with UCSF Chimera ([@bib59]). Fourier shell correlations between the final models and maps were calculated with phenix.mtriage, and to probe for overfitting, a model refined against one half-map was likewise used to calculate FSCs between both that half-map (FSC-work) and the other half-map (FSC-test) ([@bib2]) ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}, [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}, [Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}, [Figure 5---figure supplement 6](#fig5s6){ref-type="fig"}).

Classification of cryo-EM data against synthetic templates and calculation of interfaced octamer odds ratios {#s4-8}
------------------------------------------------------------------------------------------------------------

The five interface-centered filament particle stacks were re-extracted to a larger box size and a common pixel size (2 Å/px) and a larger box size (576 Å) that completely included both interfaced octamers ([Figure 5---figure supplement 8A](#fig5s8){ref-type="fig"}). Synthetic templates representing different octamer conformations and orientations for either of these interfaced octamers were prepared using a subset of the final experimental models, and simulating EM density using the Eman2 tool pdb2mrc ([@bib72]) ([Figure 5---figure supplement 8B](#fig5s8){ref-type="fig"}). The paired octamers from each interface were then classified in Relion for a single iteration, without additional alignment, using masks to focus on one octamer or the other. Odds ratios (and associated 95% confidence intervals) were then calculated for all possible pairs of classified conformations between the sets of interfaced octamers (([Figure 5---figure supplement 8C](#fig5s8){ref-type="fig"}, ([Figure 5---figure supplements 9](#fig5s9){ref-type="fig"}--[13](#fig5s13){ref-type="fig"}).
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Data availability {#s7}
=================

The cryo-EM maps described here have been deposited in the Electron Microscopy Data Bank with accession numbers 20687, 20688, 20690, 20691, 20701, 20704, 20705, 20706, 20707, 20709, 20716, 20718, 20720, 20722, 20723, 20725, 20742, 20741, and 20743. The refined atomic coordinates have been deposited in the Protein Data Bank with accession numbers 6U8E, 6U8N, 6U8R, 6U8S, 6U9O, 6UA2, 6UA4, 6UA5, 6UAJ, 6UC2, 6UDP, 6UDO, and 6UDQ.

The following datasets were generated:

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP, NAD+ assembly interface cryo-EM mapElectron Microscopy Data Bank20687

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP, NAD+ assembly interface atomic modelProtein Data Bank6U8E

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP, NAD+ fully extended cryo-EM mapElectron Microscopy Data Bank20688

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP, NAD+ fully extended atomic modelProtein Data Bank6U8N

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP, NAD+ Bent (1:3) cryo-EM mapElectron Microscopy Data Bank20690

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP, NAD+ Bent (1:3) atomic modelProtein Data Bank6U8R

JohnsonMCKollmanJM2019IMPDH2 ATP, NAD+ assembly interface cryo-EM mapElectron Microscopy Data Bank20718

JohnsonMCKollmanJM2019IMPDH2 ATP, NAD+ fully extended cryo-EM mapElectron Microscopy Data Bank20716

JohnsonMCKollmanJM2019IMPDH2 ATP, NAD+ fully compressed cryo-EM mapElectron Microscopy Data Bank20709

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP assembly interface cryo-EM mapElectron Microscopy Data Bank20723

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP fully extended cryo-EM mapElectron Microscopy Data Bank20722

JohnsonMCKollmanJM2019IMPDH2 ATP, IMP fully compressed cryo-EM mapElectron Microscopy Data Bank20720

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP free octamerElectron Microscopy Data Bank20725

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP free octamerProtein Data Bank6UC2

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP assembly interfaceElectron Microscopy Data Bank20742

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP assembly interfaceProtein Data Bank6UDP

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP fully compressedElectron Microscopy Data Bank20741

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP fully compressedProtein Data Bank6UDO

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP fully compressed endElectron Microscopy Data Bank20743

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP fully compressed endProtein Data Bank6UDQ

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ assembly interface cryo-EM mapElectron Microscopy Data Bank20691

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ assembly interface atomic modelProtein Data Bank6U8S

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ bent (2:2) cryo-EM mapElectron Microscopy Data Bank20704

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ bent (2:2) atomic modelProtein Data Bank6UA2

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ bent (3:1) cryo-EM mapElectron Microscopy Data Bank20705

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ bent (3:1) atomic modelProtein Data Bank6UA4

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ fully compressed cryo-EM mapElectron Microscopy Data Bank20701

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ fully compressed atomic modelProtein Data Bank6U9O

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ free octamer cryo-EM mapElectron Microscopy Data Bank20707

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ free octamer atomic modelProtein Data Bank6UAJ

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ free interfacial octamer cryo-EM mapElectron Microscopy Data Bank20706

JohnsonMCKollmanJM2019IMPDH2 ATP, GTP, IMP, NAD+ free interfacial octamer atomic modelProtein Data Bank6UA5

10.7554/eLife.53243.sa1

Decision letter

Scheres

Sjors HW

Reviewing Editor

MRC Laboratory of Molecular Biology

United Kingdom

Scheres

Sjors HW

Reviewer

MRC Laboratory of Molecular Biology

United Kingdom

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Human IMPDH2 forms filaments and other higher order structures when the enzyme inhibited and guanine nucleotide pools are depressed. Curiously, this structural transformation appears to have very little effect on enzymatic activity. This paper reports a series of EM structures of filaments formed under different ligand conditions, revealing several different conformational states. Based on these structures, the authors propose an elegant mechanism of allosteric regulation where filament formation regulates GTP feedback inhibition that may at last explain the mysterious physiological role of filament formation. This is an intriguing and potentially very important contribution. It was noted that IMPDH is a major target of immunosuppressive drugs such as mycophenolic acid. As such, a deeper structural understanding of its regulation has implications for further refinements to this class of drugs.

**Decision letter after peer review:**

Thank you for submitting your article \"Ensemble cryo-EM structures demonstrate human IMPDH2 filament assembly tunes allosteric regulation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Sjors HW Scheres as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Cynthia Wolberger as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essential revisions:

1\) The enzyme preparation appears to be much less active (by a factor of 20) than those reported from other laboratories. The value of kcat is typically in approx. 1 s^-1^ (see BRENDA website). Figure 2D reports a specific activity of approx. 50 nmoles NADH produced per min per mg of enzyme. Converting (please check the math):

(50 nmoles min-1mg-1) divided by 60 s min-1 = \~0.9 nmoles s^-1^ mg-1

1 x 10-3 g IMPDH divided 55,000 g/mol = 18 nmoles

0.9 nmole s^-1^ mg -1 divided 18 nmoles mg-1 = \~ 0.05 s^-1^

If only 5% of the enzyme is active, then the relevance of these structures is in doubt. It is possible that this discrepancy arises from issues with the assay itself rather than the integrity of the enzyme preparation. The description of the assay does not include the enzyme concentration. However, samples were taken directly from the assay for structural work, which suggests that the concentration in the assay may have been 2 uM. This is a very high concentration. If the enzyme were as active as observed in other laboratories, the rate of NADH production would be:

2 μm x 1 s^-1^ x 60 s/min = 120 μm min-1

The starting substrate concentrations were 2 mM- all the substrate would be consumed during the 20 min assay. The rates were measured starting 3 min after initiation (unclear why), at a point where approximately 20% of the substrates would have been consumed, so the reaction is no longer under initial rate conditions. The resulting products would be expected to inhibit the reaction. Note that NAD inhibits at high concentrations, adding another complication. So it is quite possible that the assays did not accurately measure enzyme activity.

2\) Another concern is the potential for inadvertent changes in reaction conditions at high nucleotide concentrations. The buffer contains 100 mM KCl and only 20 mM Hepes, and pH 7 is at the lower end of its useful range. Concentrations of nucleotides go as high as 20 mM in the experiments, which could change pH and also affect ionic strength. Was the pH checked?

3\) The authors do not describe the reagents- it is important to include which salts of IMP, ATP, etc. are used. In particular, the behavior of ATP can change markedly depending on whether Na or Mg salts were used. The enzyme is activated by monovalent cations, and the monovalent cation binding site lies at or near the octamer interface. Changes in the nature of the monovalent cation could also change the octamer interface. This is a question for another day, but it would be good to know what monovalent cations are present in the reactions. For example, the disodium ATP salt is one of the most commonly used ATP reagents- at 20 mM ATP, the sodium concentration would be 40 mM. The Km for Na is similar to K, so approx. 30% monomers would contain Na instead of K.

4\) The regulation of metabolic enzyme polymerization appears to act, primarily, by altering the affinity of the \"monomer\" for the end of the polymer. Basically, small molecule binding to the monomer shifts the equilibrium distribution of the protein between the monomer/filament states. The effect of GTP on the filament curvature suggests that it is incorporating into the filament, altering the structure and destabilizing it. This could have two roles: 1) if the filament strain is sufficient, the filament could break. This would accelerate disassembly by increasing the number of ends available for depolymerization since this is an end limited process or 2) the only relevant strain is at the ends, where is accelerates subunit loss from the filament. While these are not mutually exclusive, it should be possible to tease these possibilities apart by looking at the length distribution of filaments at very low GTP concentration and/or short time points. Given the ensemble nature of IMPDH filaments and the fact that the authors have some of the titration data already, it shouldn\'t be too burdensome to take a look at the role of the strained conformation in promoting disassembly. It could be that the authors already have sufficient data at hand to address this based on the fact that the filaments are more resistant to the effects of GTP than the monomer arguing that the effects are at the level of the filament. Further clarification of this would be helpful.

5\) One could analyse the orientations and classes of individual particle images along each filament to get an idea about the extended/compressed conformations of the Bateman domains in subsequent octamers inside each filaments. This could lead to insights whether these conformations are directly related to the filaments bending in a specific direction, e.g. are compressed conformations on the inside of bends? Was such an analysis attempted?

6\) Despite atomic-model refinements, no FSCs between models and maps are presented. This should be remediated in a revised version. Three curves should be shown for each map in which an atomic model was refined: a) between the final map and the final model; b) between a model refined in one of the half-maps against that same half-map (FSC-work); and c) of the same model from b) against the other half-map (FSC-test). A large difference between FSC-work and FSC-test should be avoided (by adjusting weights in refinement), as they would be an indication of overfitting.
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Author response

> Essential revisions:
>
> 1\) The enzyme preparation appears to be much less active (by a factor of 20) than those reported from other laboratories. The value of kcat is typically in approx. 1 s^-1^ (see BRENDA website). Figure 2D reports a specific activity of approx. 50 nmoles NADH produced per min per mg of enzyme. Converting (please check the math):
>
> (50 nmoles min-1mg-1) divided by 60 s min-1 = \~0.9 nmoles s^-1^ mg-1
>
> 1 x 10-3 g IMPDH divided 55,000 g/mol = 18 nmoles
>
> 0.9 nmole s^-1^ mg -1 divided 18 nmoles mg-1 = \~ 0.05 s^-1^
>
> If only 5% of the enzyme is active, then the relevance of these structures is in doubt. It is possible that this discrepancy arises from issues with the assay itself rather than the integrity of the enzyme preparation. The description of the assay does not include the enzyme concentration. However, samples were taken directly from the assay for structural work, which suggests that the concentration in the assay may have been 2 uM. This is a very high concentration. If the enzyme were as active as observed in other laboratories, the rate of NADH production would be:
>
> 2 μm x 1 s^-1^ x 60 s/min = 120 μm min-1
>
> The starting substrate concentrations were 2 mM- all the substrate would be consumed during the 20 min assay. The rates were measured starting 3 min after initiation (unclear why), at a point where approximately 20% of the substrates would have been consumed, so the reaction is no longer under initial rate conditions. The resulting products would be expected to inhibit the reaction. Note that NAD inhibits at high concentrations, adding another complication. So it is quite possible that the assays did not accurately measure enzyme activity.

For our kinetic assays, the protein concentration was, in fact, 2 uM, and we now note this in the Materials and methods section. This protein concentration was selected because it was the optimum for cryo-EM particle dispersion, and we felt it necessary that our kinetic experiments be performed under identical conditions as our EM experiments. The timeframe in which we measure reaction velocities is in the linear range of the activity assays, and we now show representative traces of NADH generated vs. time in Figure 2---figure supplement 2A,B for a range of protein concentrations.

Indeed, the activity levels we report are lower than some previous studies have found for human IMPDH2. One major consideration is temperature -- we perform our experiments at 24**°**C, while most others have reported activities at 37**°**C. We see an \~3-fold increase in activity at 37**°**C. We also see a minor effect of enzyme concentration, with higher concentrations having a slightly lower activity (data now included as Figure 2 ---figure supplement 2C). At the higher temperature, our kcat is similar to the most recently reported literature value of 0.18 s^-1^ (Fernández-Justel et al., 2019). Importantly, that study and ours were similar in working at high enzyme concentrations (1.8 and 2 uM). Moreover, these are the only two studies we are aware of that have included careful biophysical characterization of the enzyme used in biochemical assays (SAXS and negative stain EM in Fernández-Justel, et al. and cryo-EM in our paper); this is likely important as, in our hands at least, non-specific aggregation of IMPDH2 is a common problem that might have influenced activity in other studies.

> 2\) Another concern is the potential for inadvertent changes in reaction conditions at high nucleotide concentrations. The buffer contains 100 mM KCl and only 20 mM Hepes, and pH 7 is at the lower end of its useful range. Concentrations of nucleotides go as high as 20 mM in the experiments, which could change pH and also affect ionic strength. Was the pH checked?

In responding to this comment we realized an error in the manuscript: the final pH for all kinetic assays and EM preparations was 7.5, not 7; the revised manuscript contains this correction. The final pH for all reagents, including buffers, protein preparations, and nucleotide stocks, was adjusted if necessary to pH 7.5 using KOH or HCl.

> 3\) The authors do not describe the reagents- it is important to include which salts of IMP, ATP, etc. are used. In particular, the behavior of ATP can change markedly depending on whether Na or Mg salts were used. The enzyme is activated by monovalent cations, and the monovalent cation binding site lies at or near the octamer interface. Changes in the nature of the monovalent cation could also change the octamer interface. This is a question for another day, but it would be good to know what monovalent cations are present in the reactions. For example, the disodium ATP salt is one of the most commonly used ATP reagents- at 20 mM ATP, the sodium concentration would be 40 mM. The Km for Na is similar to K, so approx. 30% monomers would contain Na instead of K.

Sodium salts of ATP, GTP, and IMP were, in fact, used for these experiments. Specifically: ATP disodium salt hydrate (Sigma A2383), GTP sodium salt hydrate (Sigma G8877) and IMP disodium salt hydrate (Acros AC226260050). This information is included in the revised manuscript.

> 4\) The regulation of metabolic enzyme polymerization appears to act, primarily, by altering the affinity of the \"monomer\" for the end of the polymer. Basically, small molecule binding to the monomer shifts the equilibrium distribution of the protein between the monomer/filament states. The effect of GTP on the filament curvature suggests that it is incorporating into the filament, altering the structure and destabilizing it. This could have two roles: 1) if the filament strain is sufficient, the filament could break. This would accelerate disassembly by increasing the number of ends available for depolymerization since this is an end limited process or 2) the only relevant strain is at the ends, where is accelerates subunit loss from the filament. While these are not mutually exclusive, it should be possible to tease these possibilities apart by looking at the length distribution of filaments at very low GTP concentration and/or short time points. Given the ensemble nature of IMPDH filaments and the fact that the authors have some of the titration data already, it shouldn\'t be too burdensome to take a look at the role of the strained conformation in promoting disassembly. It could be that the authors already have sufficient data at hand to address this based on the fact that the filaments are more resistant to the effects of GTP than the monomer arguing that the effects are at the level of the filament. Further clarification of this would be helpful.

We also were curious whether the strain that induces disassembly occurs only at the filament ends, or if depolymerization can occur at any filament interface. However, we were unsuccessful in designing an experiment to address this. As explained below in more detail in our response to comment \#5, we performed calculations based on our cryo-EM data to probe whether the compressed filament conformations were more, or less, likely to be near filament ends, but our results were inconclusive. Although the GTP titration data we present in our manuscript does include low concentrations of GTP, because these samples were prepared \~30 minutes after GTP treatment any assembly/disassembly of filaments is presumed to be at equilibrium. In such a case, we would not expect the distributions of filament lengths between our two possible scenarios to be different. In theory, it should be possible to obtain the necessary data from non-equilibrium states, by preparing EM grids at different time points after GTP treatment. We have previously published results of such an experiment, in which we found that the time-scale of GTP-induced IMPDH2 filament disassembly was on the order of seconds (Duong-Ly et al., 2018). Unfortunately, given this rate of disassembly, and the technical limitations of EM grid preparation, we were not able to sample sufficient time points to obtain the data needed. We are thus forced to leave this question for future experiments.

> 5\) One could analyse the orientations and classes of individual particle images along each filament to get an idea about the extended/compressed conformations of the Bateman domains in subsequent octamers inside each filaments. This could lead to insights whether these conformations are directly related to the filaments bending in a specific direction, e.g. are compressed conformations on the inside of bends? Was such an analysis attempted?

In response to this comment, we have performed additional analysis, classifying the filament interface centered cryo-EM data against a series of synthetic templates. These interface centered particle stacks are each the consensus of all filament segments from each dataset, and each interface-centered "particle" contains two interfaced octamers. We independently classified each of the two octamers against simulated EM density templates prepared from the final atomic models. To check for correlation of conformations across the interface, we compared the classified particles using pairwise odds ratios. We have included this new analysis in the revised manuscript as Figure 5---figure supplement 8-13, and have added new passages to the Results section describing it. This analysis provides a large number of pairwise comparisons across all of our datasets, but the overall picture is one of minimal to no correlation between the conformational states of adjacent octamers in a filament.

> 6\) Despite atomic-model refinements, no FSCs between models and maps are presented. This should be remediated in a revised version. Three curves should be shown for each map in which an atomic model was refined: a) between the final map and the final model; b) between a model refined in one of the half-maps against that same half-map (FSC-work); and c) of the same model from b) against the other half-map (FSC-test). A large difference between FSC-work and FSC-test should be avoided (by adjusting weights in refinement) as they would be an indication of overfitting.

The three types of model-map FSCs requested by the reviewer (final model-map FSC, FSC-work, and FSC-test) have been prepared for all final models and are included in the revised manuscript as Figure 3---figure supplement 2, Figure 4---figure supplement 3, Figure 4---figure supplement 5, Figure 5---figure supplement 5, and Figure 5---figure supplement 6.
